

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS	3	MAR 16	CASREACT coverage extended
NEWS	4	MAR 20	MARPAT now updated daily
NEWS	5	MAR 22	LWPI reloaded
NEWS	6	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS	7	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS	8	APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS	9	APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS	10	APR 30	CA/CAPplus enhanced with 1870-1889 U.S. patent records
NEWS	11	APR 30	INPADOC replaced by INPADOCDB on STN
NEWS	12	MAY 01	New CAS web site launched
NEWS	13	MAY 08	CA/CAPplus Indian patent publication number format defined
NEWS	14	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS	15	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS	16	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS	17	MAY 21	CA/CAPplus enhanced with additional kind codes for German patents
NEWS	18	MAY 22	CA/CAPplus enhanced with IPC reclassification in Japanese patents
NEWS	19	JUN 27	CA/CAPplus enhanced with pre-1967 CAS Registry Numbers
NEWS	20	JUN 29	STN Viewer now available
NEWS	21	JUN 29	STN Express, Version 8.2, now available
NEWS	22	JUL 02	LEMBASE coverage updated
NEWS	23	JUL 02	LMEDLINE coverage updated
NEWS	24	JUL 02	SCISEARCH enhanced with complete author names
NEWS	25	JUL 02	CHEMCATS accession numbers revised
NEWS	26	JUL 02	CA/CAPplus enhanced with utility model patents from China
NEWS	27	JUL 16	CAPplus enhanced with French and German abstracts
NEWS	28	JUL 18	CA/CAPplus patent coverage enhanced
NEWS	29	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS	30	JUL 30	USGENE now available on STN

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 20:07:32 ON 30 JUL 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 20:07:40 ON 30 JUL 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 JUL 2007 HIGHEST RN 943590-78-1

DICTIONARY FILE UPDATES: 29 JUL 2007 HIGHEST RN 943590-78-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10500840.str



chain nodes :

20 21

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

chain bonds :

8-10 9-20 18-21

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 10-11 10-15 11-12 12-13 13-14
14-15 14-16 15-18 16-17 17-18

exact/norm bonds :

6-9 8-9 14-16 15-18 16-17 17-18

exact bonds :

5-7 7-8 8-10 9-20 18-21

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15
isolated ring systems :
containing 1 : 10 :

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 20:CLASS
21:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 20:07:58 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 13 TO ITERATE

100.0% PROCESSED 13 ITERATIONS
SEARCH TIME: 00.00.01

4 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 44 TO 476
PROJECTED ANSWERS: 4 TO 200

L2 4 SEA SSS SAM L1

=> s l1

SAMPLE SEARCH INITIATED 20:08:04 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 13 TO ITERATE

100.0% PROCESSED 13 ITERATIONS
SEARCH TIME: 00.00.01

4 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 44 TO 476
PROJECTED ANSWERS: 4 TO 200

L3 4 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 20:08:08 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 392 TO ITERATE

100.0% PROCESSED 392 ITERATIONS 113 ANSWERS
SEARCH TIME: 00.00.01

L4 113 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 172.10 172.31

FILE 'CAPLUS' ENTERED AT 20:08:13 ON 30 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Jul 2007 VOL 147 ISS 6
FILE LAST UPDATED: 29 Jul 2007 (20070729/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l4 full
L5 3 L4

=> d ibib abs hitstr tot

L5 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:791806 CAPLUS
DOCUMENT NUMBER: 145:217964
TITLE: Crystalline 7-[5-[(cyclohexylmethylamino)methyl]-1H-indol-2-yl]-2-methyl-1H-imidazo[4,5-b]pyridin-5-amine sulfate trihydrate and its pharmaceutical uses
INVENTOR(S): Chase, Charles E.; Kushida, Ikuro
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
SOURCE: PCT Int. Appl., 45pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006083908	A1	20060810	WO 2006-US3463	20060201
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,			

MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
 SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
 VN, YU, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM

US 2006194833 A1 20060831 US 2006-344534 20060201

PRIORITY APPLN. INFO.: US 2005-648701P P 20050202

AB The invention relates to crystalline 7-[5-[(cyclohexylmethylamino)methyl]-1H-indol-2-yl]-2-methyl-1H-imidazo[4,5-b]pyridin-5-amine sulfate trihydrate (E 6070), its method of preparation, and its therapeutic uses. Pharmaceutical compns. containing crystalline E 6070 and a acceptable carrier represent one embodiment of the invention. The invention also relates to methods for treating an inflammatory disorder, an autoimmune disorder, or a proliferative disorder comprising the step of administering to a patient in need thereof a therapeutically effective amount of crystalline E 6070. The compound was prepared and characterized by x-ray diffraction studies.

IT 532391-43-8P, E 6070

RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)

(crystalline (cyclohexylmethylamino)methylindolylmethylimidazopyridinamine and its pharmaceutical uses)


RN 532391-43-8 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylmethylamino)methyl]-1H-indol-2-yl]-2-methyl-, sulfate (1:1), trihydrate (9CI) (CA INDEX NAME)

CM 1

CRN 532391-42-7


CMF C23 H28 N6



CM 2

CRN 7664-93-9

CMF H2 O4 S




IT 532391-42-7, ER 807447

RL: RCT (Reactant); RACT (Reactant or reagent)

(crystalline (cyclohexylmethylamino)methylindolylmethylimidazopyridinamine and its pharmaceutical uses)

RN 532391-42-7 CAPLUS



CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylmethylamino)methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:780361 CAPLUS
 DOCUMENT NUMBER: 141:295778
 TITLE: Preparation of deazapurines for use in pharmaceutical compositions for the treatment of reperfusion injuries, osteoporosis and/or bone metastasis
 INVENTOR(S): Daun, Jane; Fields, Scott; Kobayashi, Seiichi
 PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
 SOURCE: U.S. Pat. Appl. Publ., 178 pp., Cont.-in-part of WO 2003 57,696.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004186127	A1	20040923	US 2004-753261	20040107
WO 2003057696	A1	20030717	WO 2003-US366	20030107
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1707566	A1	20061004	EP 2006-5483	20030107
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			US 2002-346598P	P 20020107
			WO 2003-US300366	A2 20030107
			EP 2003-729359	A3 20030107
OTHER SOURCE(S):			MARPAT 141:295778	
GI				



AB Deazapurines, such as I [R1 = H, NH2, NHMe, NHAc, OH, F, OMe, CN, NHCO2Et; R2 = H, NRaRb, ORa, aliphatic, heteroaliph., aryl, heteroaryl, etc.; Ra, Rb = H, aliphatic, heteroaliph., aryl, heteroaryl; R3 = H, CN, halogen, heteroaryl, amino, carbamoyl, etc.], were prepared for treatment of reperfusion injuries, osteoporosis and/or bone metastasis. Thus, deazapurine II was prepared via a multistep synthetic sequence starting from Me indole-5-carboxylate, di-tert-Bu dicarbonate, tributylstannane, 5,6-diamino-4-chloro-2-pyridinyl-carbamic acid Et ester, tri-Et orthocarbonate, and phthalimide. The prepared deazapurines were assayed for cellular cytokine inhibition using human umbilical vein endothelial cells (HUVEC).

IT 761458-54-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(ER 809047; preparation of deazapurines for use in pharmaceutical compns. for the treatment of reperfusion injuries, osteoporosis and/or bone metastasis)


RN 761458-54-2 CAPLUS

CN 1H-Indole-5-carboxylic acid, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 562083-98-1

CMF C16 H13 N5 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT 562083-93-6P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of deazapurines for use in pharmaceutical compns. for the treatment of reperfusion injuries, osteoporosis and/or bone metastasis)

RN 562083-93-6 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[(1E)-2-cyclohexylethenyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 561307-06-0P, ER 806274 561307-07-1P, ER 805094

562077-48-9P 562077-49-0P 562077-50-3P
562077-51-4P 562077-52-5P 562077-53-6P
562077-54-7P 562077-55-8P 562077-56-9P
562077-57-0P 562077-59-2P 562077-61-6P
562077-97-8P 562078-00-6P 562078-08-4P
562078-10-8P 562078-35-7P 562078-70-0P
562079-06-5P 562079-30-5P 562079-63-4P
562079-95-2P 562080-38-0P 562080-50-6P
562081-01-0P, ER 806333 562081-02-1P
562081-16-7P 562081-19-0P 562081-25-8P
562081-26-9P 562081-27-0P 562081-28-1P
562081-31-6P 562081-32-7P 562081-59-8P
562081-60-1P 562081-61-2P 562081-62-3P
562081-63-4P 562081-64-5P 562081-67-8P
562081-83-8P 562081-88-3P 562081-89-4P
562081-90-7P 562081-91-8P 562081-92-9P
562081-93-0P 562081-94-1P 562081-95-2P
562081-96-3P 562081-97-4P, ER 806820
562081-98-5P 562082-38-6P 562082-59-1P
562082-68-2P 562082-85-3P 562082-86-4P
562082-87-5P 562082-88-6P 562082-89-7P
562082-90-0P 562082-91-1P 562082-92-2P, ER
806987 562082-93-3P 562082-94-4P, ER 807140
562082-95-5P 562082-96-6P 562082-97-7P
562082-98-8P 562083-00-5P 562083-01-6P
562083-02-7P 562083-04-9P 562083-39-0P
562083-41-4P 562083-42-5P 562083-43-6P

562083-44-7P 562083-46-9P 562083-49-2P

562083-50-5P 562083-83-4P 562083-84-5P


562083-94-7P 562083-99-2P 562084-05-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of deazapurines for use in pharmaceutical compns. for the treatment of reperfusion injuries, osteoporosis and/or bone metastasis)


RN 561307-06-0 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[methyl(phenylmethyl)amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 561307-07-1 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[[[(3-chlorophenyl)methyl]methylamino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562077-48-9 CAPLUS

CN 1H-Indole-5-carbonitrile, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)- (9CI) (CA INDEX NAME)




RN 562077-49-0 CAPLUS


CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-(1H-indol-2-yl)-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 562077-50-3 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-ethyl-7-(1H-indol-2-yl)- (9CI) (CA INDEX NAME)




RN 562077-51-4 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-(1H-indol-2-yl)-2-propyl- (9CI) (CA INDEX NAME)



RN 562077-52-5 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-butyl-7-(1H-indol-2-yl)- (9CI) (CA INDEX NAME)




RN 562077-53-6 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-(1H-indol-2-yl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 562077-54-7 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-(1H-indol-2-yl)-2-[(4-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 562077-55-8 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-(4-morpholinylmethyl)-1H-indol-2-yl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 562077-56-9 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-ethoxy-7-[5-(4-morpholinylmethyl)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562077-57-0 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-[(4-methylphenyl)methyl]-7-[5-(4-morpholinylmethyl)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562077-59-2 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-[4-(methylthio)phenyl]-7-[5-(4-morpholinylmethyl)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562077-61-6 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-(4-methoxyphenyl)-7-[5-(4-morpholinylmethyl)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562077-97-8 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-(1-piperidinylmethyl)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562078-00-6 CAPLUS

CN Piperazine, 1-acetyl-4-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]- (9CI) (CA INDEX NAME)




RN 562078-08-4 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[[[(4-methoxyphenyl)methyl]amino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562078-10-8 CAPLUS

CN Methanone, [1-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]-4-piperidinyl]phenyl- (9CI) (CA INDEX NAME)



RN 562078-35-7 CAPLUS


CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[[[bis(2-methoxyethyl)amino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 562078-70-0 CAPLUS


CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[methyl[2-(2-methoxyethyl)amino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)

pyridinyl)ethyl]amino)methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562079-06-5 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino)methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562079-30-5 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[methyl[(3,4,5-trimethoxyphenyl)methyl]amino)methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562079-63-4 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[methyl(2-phenylethyl)amino)methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562079-95-2 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[[2-(2-pyridinyl)ethyl]amino)methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)



RN 562080-38-0 CAPLUS


CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[[[(4-chlorophenyl)methyl]amino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 562080-50-6 CAPLUS

CN Butanamide, 2-[[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]amino]-4-(methylthio)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 562081-01-0 CAPLUS


CN L-Alanine, N-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]-3-(ethylphenylamino)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 562081-02-1 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[[ethyl(phenylmethyl)amino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562081-16-7 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[(ethylphenylamino)methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562081-19-0 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[phenylmethylamino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562081-25-8 CAPLUS
 CN Benzenesulfonamide, 4-[[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 562081-26-9 CAPLUS
 CN Benzenepropanamide, α -[[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]amino]-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 562081-27-0 CAPLUS
 CN 1H-Indole-3-propanamide, α -[[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]amino]-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 562081-28-1 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[(phenylamino)methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562081-31-6 CAPLUS

CN Methanone, [1-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]-4-piperidinyl](4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 562081-32-7 CAPLUS

CN Methanone, [1-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]-4-piperidinyl](4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 562081-59-8 CAPLUS


CN Methanone, [1-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]-4-piperidinyl](4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 562081-60-1 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[2-pyridinylmethyl)amino)methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562081-61-2 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[methyl(2-methylpropyl)amino)methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562081-62-3 CAPLUS
 CN L-Alanine, N-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]carbonyl]-3-(ethylphenylamino)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 562081-63-4 CAPLUS
 CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 562081-64-5 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 562081-67-8 CAPLUS


CN Glycine, N-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]-N-(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 562081-83-8 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(1S)-2-amino-1-[(ethylphenylamino)methyl]-2-oxoethyl]-2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 562081-88-3 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[methyl[(1R)-1-phenylethyl]amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 562081-89-4 CAPLUS


CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[methyl[(1S)-1-phenylethyl]amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 562081-90-7 CAPLUS


CN Piperazine, 1-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]carbonyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 562081-91-8 CAPLUS


CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(1S)-1-[(ethylphenylamino)methyl]-2-(methylamino)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 562081-92-9 CAPLUS


CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[[[(3-methoxyphenyl)methyl]methylamino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 562081-93-0 CAPLUS


CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(1S)-2-(ethylamino)-1-[(ethylphenylamino)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 562081-94-1 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[2-(ethylphenylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 562081-95-2 CAPLUS


CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[2-methoxy-1-(methoxymethyl)ethyl]- (9CI) (CA INDEX NAME)



RN 562081-96-3 CAPLUS

CN 1H-Indole-6-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(1S)-1-[(ethylphenylamino)methyl]-2-(methylamino)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 562081-97-4 CAPLUS


CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(1S)-1-[(ethylamino)carbonyl]-3-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 562081-98-5 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(2-chlorophenyl)methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 562082-38-6 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(3-chlorophenyl)methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 562082-59-1 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(4-chlorophenyl)methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 562082-68-2 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[6-[[methyl(phenylmethyl)amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562082-85-3 CAPLUS

CN Methanone, [1-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-6-yl]methyl]-4-piperidinyl](4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 562082-86-4 CAPLUS


CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[6-(4-morpholinylmethyl)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)



RN 562082-87-5 CAPLUS


CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(1R)-1-[(ethylamino)carbonyl]-3-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 562082-88-6 CAPLUS

CN Piperidine, 1-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-6-yl]carbonyl]-4-(4-fluorobenzoyl)- (9CI) (CA INDEX NAME)



RN 562082-89-7 CAPLUS


CN Morpholine, 4-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-6-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 562082-90-0 CAPLUS


CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[[[(2-chlorophenyl)methyl]methylamino]methyl]-1H-indol-6-yl]carbonyl]-

no]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562082-91-1 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[[[(4-chlorophenyl)methyl]methylamino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562082-92-2 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(4-methoxyphenyl)methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 562082-93-3 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-methyl- (9CI) (CA INDEX NAME)




RN 562082-94-4 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[[[(4-methoxyphenyl)methyl]methylamino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562082-95-5 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(2-methoxyphenyl)methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 562082-96-6 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[[[(2-methoxyphenyl)methyl]methylamino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562082-97-7 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[[methyl[[3-(trifluoromethoxy)phenyl]methyl]amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562082-98-8 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[[methyl[[4-(trifluoromethoxy)phenyl]methyl]amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562083-00-5 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[[[(3,4-dichlorophenyl)methyl]methylamino]methyl]-1H-indol-2-yl]-2-methyl- (9CI)
(CA INDEX NAME)




RN 562083-01-6 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[[methyl][2-(trifluoromethoxy)phenyl]methyl]amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562083-02-7 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[[2-(furan-2-ylmethyl)methylamino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 562083-04-9 CAPLUS


CN 1H-Isoindole-1,3(2H)-dione, 2-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]- (9CI) (CA INDEX NAME)



RN 562083-39-0 CAPLUS


CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[(1Z)-2-phenylethenyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 562083-41-4 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-(2-phenylethyl)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)



RN 562083-42-5 CAPLUS


CN 1H-Indole-5-methanol, 2-((5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl)carbamoyl-3-(ethylphenylamino)- (9CI) (CA INDEX NAME)



RN 562083-43-6 CAPLUS


CN L-Alanine, N-[[2-((5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl)carbamoyl]-3-(ethylphenylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 562083-44-7 CAPLUS

CN Benzamide, N-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 562083-46-9 CAPLUS

CN Benzamide, N-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]-N-methyl- (9CI) (CA INDEX NAME)




RN 562083-49-2 CAPLUS

CN Cyclohexanone, 4-[[[2-(5-amino-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]methylamino]- (9CI) (CA INDEX NAME)




RN 562083-50-5 CAPLUS

CN Cyclohexanone, 4-[[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]methylamino]-, O-methyloxime (9CI) (CA INDEX NAME)




RN 562083-83-4 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylsulfinyl)methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562083-84-5 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylsulfonyl)methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562083-94-7 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-(2-cyclohexylethyl)-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562083-99-2 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 7-(1H-indol-2-yl)- (9CI) (CA INDEX NAME)



RN 562084-05-3 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[methyl(4-methylenecyclohexyl)amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




IT 562083-81-2

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of deazapurines for use in pharmaceutical compns. for the treatment of reperfusion injuries, osteoporosis and/or bone metastasis)

RN 562083-81-2 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylthio)methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)



IT 561307-19-5P 562083-10-7P 562083-34-5P

562083-35-6P 562083-36-7P 562083-37-8P

562083-38-9P 562083-47-0P 562083-59-4P


562083-74-3P 562083-90-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of deazapurines for use in pharmaceutical compns. for the treatment of reperfusion injuries, osteoporosis and/or bone metastasis)


RN 561307-19-5 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562083-10-7 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[4-(trifluoromethyl)phenoxy]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562083-34-5 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[(phenylthio)methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562083-35-6 CAPLUS

CN 4-Piperidinone, 1-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]- (9CI) (CA INDEX NAME)




RN 562083-36-7 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[(1-oxido-4-thiomorpholinyl)methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562083-37-8 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[(phenylmethoxy)methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562083-38-9 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-(phenylethynyl)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)



RN 562083-47-0 CAPLUS


CN Cyclohexanone, 4-[[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]methylamino]- (9CI) (CA INDEX NAME)



RN 562083-59-4 CAPLUS


CN Cyclohexanol, 4-[[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]methylamino]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 562083-74-3 CAPLUS

CN Cyclohexanol, 4-[[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]methylamino]-1-methyl- (9CI) (CA INDEX NAME)



RN 562083-90-3 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[(3-cyclohexen-1-yl)methylamino)methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)



L5 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:551516 CAPLUS

DOCUMENT NUMBER: 139:117268

TITLE: Preparation of deazapurines for use in pharmaceutical compositions for the treatment of inflammatory, autoimmune and proliferative diseases

INVENTOR(S): Daun, Jane; Davis, Heather A.; Gusovsky, Fabian; Hishinuma, Ieharu; Jiang, Yimin; Kaneko, Toshihiko; Kikuchi, Kouichi; Kobayashi, Seiichi; Lescarbeau, Andre; Li, Xiang-Li; Muramoto, Kenzo; Oh, Norihito; Pesant, Marc; Seletsky, Boris M.; Soejima, Motohiko; Yao, Ye; Yokohama, Hiromitsu; Zhao, Janet Y.; Zheng, Wanjun; Tremblay, Lynda

PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan

SOURCE: PCT Int. Appl., 215 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003057696	A1	20030717	WO 2003-US366	20030107
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2472479	A1	20030717	CA 2003-2472479	20030107
AU 2003235741	A1	20030724	AU 2003-235741	20030107
BR 2003006785	A	20041109	BR 2003-6785	20030107
EP 1474425	A1	20041110	EP 2003-729359	20030107
EP 1474425	B1	20060524		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005124649	A1	20050609	US 2003-500840	20030107
CN 1630657	A	20050622	CN 2003-805508	20030107
JP 2005524621	T	20050818	JP 2003-558011	20030107
AT 327236	T	20060615	AT 2003-729359	20030107
PT 1474425	T	20060929	PT 2003-729359	20030107
EP 1707566	A1	20061004	EP 2006-5483	20030107
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
ES 2262996	T3	20061201	ES 2003-3729359	20030107
WO 2004063336	A2	20040729	WO 2004-US293	20040107
WO 2004063336	A3	20040826		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
US 2004186127	A1	20040923	US 2004-753261	20040107
MX 2004PA06614	A	20041004	MX 2004-PA6614	20040706
IN 2004KN00999	A	20060505	IN 2004-KN999	20040716
ZA 2004006272	A	20051116	ZA 2004-6272	20040805
NO 2004003290	A	20040922	NO 2004-3290	20040806
PRIORITY APPLN. INFO.:			US 2002-346598P	P 20020107
			EP 2003-729359	A3 20030107
			WO 2003-US366	W 20030107

OTHER SOURCE(S): MARPAT 139:117268
GI



AB Indolyldeazapurines, such as I [R1 = H, NH2, alkylamino, acylamino, etc.; R2 = H, amino, alkoxy, alkyl, etc.; R3 = H, CN, halogen, heteroaryl, amino, carbamoyl, etc.], were prepared for therapeutic use as inhibitors of

cell adhesion, mol. expression and inflammatory cytokine signal transduction. These deazapurines are useful in the treatment of inflammatory, autoimmune, proliferative, central nervous system and cardiovascular diseases, such as rheumatoid arthritis, ulcerative colitis, multiple sclerosis, asthma, psoriasis, allograft rejection/graft vs. host disease, idiopathic thrombocytopenia, allergic rhinitis, atopic dermatitis, systemic lupus, glomerulonephritis, diabetes, ulcerative colitis/Crohn's disease, erythematosis, eczema, urticaria, myasthenia gravis, idiopathic thrombocytopenia purpura and cancer. Thus, deazapurine II was prepared via a coupling reaction of the corresponding halodeazapurine with 2-(tributylstannyl)-1H-indole-1-carboxylic acid 1,1-dimethylethyl ester. The prepared deazapurines were assayed for cellular cytokine inhibition using human umbilical vein endothelial cells (HUVEC).

IT 562081-62-3P, ER 806393 562083-38-9P, ER 806644
562083-47-0P, ER 807586 562083-59-4P, ER 807790
562083-81-2P, ER 808036 562083-93-6P, ER 808281
562084-05-3P, ER 807835


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of indolyldeazapurines for use in pharmaceutical compns. for treatment of inflammatory, autoimmune and proliferative diseases)

RN 562081-62-3 CAPLUS


CN L-Alanine, N-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]carbonyl]-3-(ethylphenylamino)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 562083-38-9 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-(phenylethynyl)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)



RN 562083-47-0 CAPLUS


CN Cyclohexanone, 4-[[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]methylamino]- (9CI) (CA INDEX NAME)



RN 562083-59-4 CAPLUS


CN Cyclohexanol, 4-[[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]methylamino]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 562083-81-2 CAPLUS


CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylthio)methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562083-93-6 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[(1E)-2-cyclohexylethenyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 562084-05-3 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[methyl(4-methylenecyclohexyl)amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)



IT 561307-06-0P 561307-07-1P 562077-48-9P, ER
 806014 562077-49-0P, ER 806006 562077-50-3P, ER 805985
 562077-51-4P, ER 805984 562077-52-5P, ER 806002
 562077-53-6P, ER 805969 562077-54-7P, ER 805971
 562077-55-8P, ER 806007 562077-56-9P, ER 806011
 562077-57-0P, ER 805972 562077-59-2P, ER 805997
 562077-61-6P, ER 806010 562077-97-8P, ER 806123
 562078-00-6P, ER 806136 562078-08-4P, ER 806221
 562078-10-8P, ER 806220 562078-35-7P, ER 806224
 562078-70-0P, ER 806228 562079-06-5P, ER 806276
 562079-30-5P, ER 806275 562079-63-4P, ER 806273
 562079-95-2P, ER 806317 562080-38-0P, ER 806320
 562080-50-6P, ER 806329 562081-01-0P, ER 806333
 562081-02-1P, ER 806336 562081-16-7P, ER 806358
 562081-19-0P, ER 806359 562081-25-8P, ER 806363
 562081-26-9P, ER 806362 562081-27-0P, ER 806361
 562081-28-1P, ER 806368 562081-31-6P, ER 806372
 562081-32-7P, ER 806373 562081-59-8P, ER 806374
 562081-60-1P, ER 806375 562081-61-2P, ER 806383
 562081-63-4P, ER 806402 562081-64-5P, ER 806417
 562081-67-8P, ER 806419 562081-83-8P, ER 806421
 562081-88-3P, ER 806435 562081-89-4P, ER 806437
 562081-90-7P, ER 806569 562081-91-8P, ER 806609
 562081-92-9P, ER 806610 562081-93-0P, ER 806647
 562081-94-1P, ER 806653 562081-95-2P, ER 806671
 562081-96-3P, ER 806790 562081-97-4P, ER 806820
 562081-98-5P, ER 806839 562082-38-6P, ER 806840
 562082-59-1P, ER 806841 562082-68-2P, ER 806842
 562082-85-3P, ER 806843 562082-86-4P, ER 806844
 562082-87-5P, ER 806860 562082-88-6P, ER 806901
 562082-89-7P, ER 806902 562082-90-0P, ER 806903
 562082-91-1P, ER 806905 562082-92-2P, ER 806987
 562082-93-3P, ER 807014 562082-94-4P, ER 807140
 562082-95-5P, ER 807183 562082-96-6P, ER 807240
 562082-97-7P, ER 807450 562082-98-8P, ER 807451
 562083-00-5P, ER 807452 562083-01-6P, ER 807460
 562083-02-7P, ER 807573 562083-04-9P, ER 806286
 562083-10-7P, ER 806287 562083-34-5P, ER 806311
 562083-35-6P, ER 806355 562083-36-7P, ER 806401
 562083-37-8P, ER 806404 562083-39-0P, ER 806645
 562083-41-4P, ER 806646 562083-42-5P, ER 806095
 562083-43-6P, ER 806420 562083-44-7P, ER 806432
 562083-46-9P, ER 807313 562083-49-2P, ER 807759
 562083-50-5P, ER 807789 562083-74-3P, ER 807837
 562083-83-4P, ER 808082 562083-84-5P, ER 808083
 562083-85-6P, ER 808103 562083-87-8P, ER 808040
 562083-90-3P, ER 808128 562083-94-7P, ER 808469
 562083-98-1P, ER 809047 562083-99-2P, IC 261
 562084-00-8P, IC 395 562084-01-9P, IC 375

562084-02-0P, IC 380 562084-03-1P, IC 416


562084-04-2P, ER 807546

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of indolyldeazapurines for use in pharmaceutical compns. for treatment of inflammatory, autoimmune and proliferative diseases)


RN 561307-06-0 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[methyl(phenylmethyl)amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 561307-07-1 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[[[(3-chlorophenyl)methyl]methylamino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562077-48-9 CAPLUS

CN 1H-Indole-5-carbonitrile, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)- (9CI) (CA INDEX NAME)




RN 562077-49-0 CAPLUS


CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-(1H-indol-2-yl)-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 562077-50-3 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-ethyl-7-(1H-indol-2-yl)- (9CI) (CA INDEX NAME)




RN 562077-51-4 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-(1H-indol-2-yl)-2-propyl- (9CI) (CA INDEX NAME)



RN 562077-52-5 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-butyl-7-(1H-indol-2-yl)- (9CI) (CA INDEX NAME)




RN 562077-53-6 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-(1H-indol-2-yl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 562077-54-7 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-(1H-indol-2-yl)-2-[(4-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 562077-55-8 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-(4-morpholinylmethyl)-1H-indol-2-yl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 562077-56-9 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-ethoxy-7-[5-(4-morpholinylmethyl)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562077-57-0 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-[(4-methylphenyl)methyl]-7-[5-(4-morpholinylmethyl)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562077-59-2 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-[4-(methylthio)phenyl]-7-[5-(4-morpholinylmethyl)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562077-61-6 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-(4-methoxyphenyl)-7-[5-(4-morpholinylmethyl)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562077-97-8 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-(1-piperidinylmethyl)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562078-00-6 CAPLUS

CN Piperazine, 1-acetyl-4-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]- (9CI) (CA INDEX NAME)




RN 562078-08-4 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[[[(4-methoxyphenyl)methyl]amino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562078-10-8 CAPLUS

CN Methanone, [1-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]-4-piperidinyl]phenyl- (9CI) (CA INDEX NAME)



RN 562078-35-7 CAPLUS


CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[[[bis(2-methoxyethyl)amino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 562078-70-0 CAPLUS


CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[methyl[2-(2-

pyridinyl)ethyl]amino)methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562079-06-5 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino)methyl]-1H-indol-2-yl]-2-methyl- (9CI)
(CA INDEX NAME)




RN 562079-30-5 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[methyl{(3,4,5-trimethoxyphenyl)methyl]amino)methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562079-63-4 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[methyl(2-phenylethyl)amino)methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562079-95-2 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[[2-(2-pyridinyl)ethyl]amino)methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)



RN 562080-38-0 CAPLUS


CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[[[(4-chlorophenyl)methyl]amino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 562080-50-6 CAPLUS

CN Butanamide, 2-[[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]amino]-4-(methylthio)-, (2S)- (9CI). (CA INDEX NAME)


Absolute stereochemistry.



RN 562081-01-0 CAPLUS


CN L-Alanine, N-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]-3-(ethylphenylamino)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 562081-02-1 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[[ethyl(phenylmethyl)amino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562081-16-7 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[(ethylphenylamino)methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562081-19-0 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[[(phenylmethyl)amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)



RN 562081-25-8 CAPLUS


CN Benzenesulfonamide, 4-[[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 562081-26-9 CAPLUS

CN Benzenepropanamide, α -[[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]amino]-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 562081-27-0 CAPLUS


CN 1H-Indole-3-propanamide, α -[[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]amino]-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 562081-28-1 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[(phenylamino)methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562081-31-6 CAPLUS

CN Methanone, [1-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]-4-piperidiny] (4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 562081-32-7 CAPLUS

CN Methanone, [1-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]-4-piperidiny] (4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 562081-59-8 CAPLUS

CN Methanone, [1-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]-4-piperidiny] (4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 562081-60-1 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[2-pyridinylmethyl)amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562081-61-2 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[methyl(2-methylpropyl)amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562081-63-4 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 562081-64-5 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 562081-67-8 CAPLUS


CN Glycine, N-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]-N-(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 562081-83-8 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(1S)-2-amino-1-[(ethylphenylamino)methyl]-2-oxoethyl]-2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 562081-88-3 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[methyl[(1R)-1-phenylethyl]amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 562081-89-4 CAPLUS


CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[methyl[(1S)-1-phenylethyl]amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 562081-90-7 CAPLUS


CN Piperazine, 1-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]carbonyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 562081-91-8 CAPLUS


CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(1S)-1-[(ethylphenylamino)methyl]-2-(methylamino)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 562081-92-9 CAPLUS


CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[[[(3-methoxyphenyl)methyl]methylamino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 562081-93-0 CAPLUS


CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(1S)-2-(ethylamino)-1-[(ethylphenylamino)methyl]-2-oxoethyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 562081-94-1 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[2-(ethylphenylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 562081-95-2 CAPLUS


CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[2-methoxy-1-(methoxymethyl)ethyl]- (9CI) (CA INDEX NAME)



RN 562081-96-3 CAPLUS

CN 1H-Indole-6-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(1S)-1-[(ethylphenylamino)methyl]-2-(methylamino)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 562081-97-4 CAPLUS


CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(1S)-1-[(ethylamino)carbonyl]-3-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 562081-98-5 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(2-chlorophenyl)methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 562082-38-6 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(3-chlorophenyl)methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 562082-59-1 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(4-chlorophenyl)methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 562082-68-2 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[6-[[methyl(phenylmethyl)amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562082-85-3 CAPLUS

CN Methanone, [1-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-6-yl]methyl]-4-piperidinyl](4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 562082-86-4 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[6-(4-morpholinylmethyl)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562082-87-5 CAPLUS
 CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(1R)-1-[(ethylamino)carbonyl]-3-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 562082-88-6 CAPLUS
 CN Piperidine, 1-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-6-yl]carbonyl]-4-(4-fluorobenzoyl)- (9CI) (CA INDEX NAME)




RN 562082-89-7 CAPLUS

CN Morpholine, 4-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-6-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 562082-90-0 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[[[(2-chlorophenyl)methyl]methylamino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562082-91-1 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[[[(4-chlorophenyl)methyl]methylamino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562082-92-2 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(4-methoxyphenyl)methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 562082-93-3 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-methyl- (9CI) (CA INDEX NAME)




RN 562082-94-4 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[[[(4-methoxyphenyl)methyl]methylamino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562082-95-5 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-N-[(2-methoxyphenyl)methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 562082-96-6 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[[[(2-methoxyphenyl)methyl]methylamino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562082-97-7 CAPLUS


CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[methyl[[3-(trifluoromethoxy)phenyl]methyl]amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562082-98-8 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[methyl[[4-(trifluoromethoxy)phenyl]methyl]amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562083-00-5 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[[[(3,4-dichlorophenyl)methyl]methylamino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 562083-01-6 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[methyl[[2-(trifluoromethoxy)phenyl]methyl]amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562083-02-7 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[[[(2-furanylmethyl)methylamino]methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562083-04-9 CAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]- (9CI) (CA INDEX NAME)




RN 562083-10-7 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[[4-(trifluoromethyl)phenoxy]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562083-34-5 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[(phenylthio)methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 562083-35-6 CAPLUS

CN 4-Piperidinone, 1-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]- (9CI) (CA INDEX NAME)




RN 562083-36-7 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[(1-oxido-4-thiomorpholinyl)methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)



RN 562083-37-8 CAPLUS


CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[(phenylmethoxy)methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)



RN 562083-39-0 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-[(1Z)-2-phenylethenyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME).


Double bond geometry as shown.



RN 562083-41-4 CAPLUS


CN 1H-Imidazo[4,5-b]pyridin-5-amine, 2-methyl-7-[5-(2-phenylethyl)-1H-indol-2-

yl]- (9CI) (CA INDEX NAME)



RN 562083-42-5 CAPLUS


CN 1H-Indole-5-methanol, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)- (9CI) (CA INDEX NAME)



RN 562083-43-6 CAPLUS


CN L-Alanine, N-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]carbonyl]-3-(ethylphenylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 562083-44-7 CAPLUS

CN Benzamide, N-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 562083-46-9 CAPLUS

CN Benzamide, N-[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]-N-methyl- (9CI) (CA INDEX NAME)




RN 562083-49-2 CAPLUS

CN Cyclohexanone, 4-[[[2-(5-amino-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]methylamino]- (9CI) (CA INDEX NAME)




RN 562083-50-5 CAPLUS

CN Cyclohexanone, 4-[[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]methylamino]-, O-methyloxime (9CI) (CA INDEX NAME)




RN 562083-74-3 CAPLUS

CN Cyclohexanol, 4-[[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-5-yl]methyl]methylamino]-1-methyl- (9CI) (CA INDEX NAME)




RN 562083-83-4 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylsulfinyl)methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562083-84-5 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylsulfonyl)methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562083-85-6 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexyloxy)methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562083-87-8 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylmethylamino)methyl]-1H-indol-2-yl]-N,2-dimethyl- (9CI) (CA INDEX NAME)




RN 562083-90-3 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[(3-cyclohexen-1-ylmethylamino)methyl]-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562083-94-7 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-(2-cyclohexylethyl)-1H-indol-2-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 562083-98-1 CAPLUS

CN 1H-Indole-5-carboxylic acid, 2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)- (9CI) (CA INDEX NAME)




RN 562083-99-2 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine, 7-(1H-indol-2-yl)- (9CI) (CA INDEX NAME)




RN 562084-00-8 CAPLUS

CN Carbamic acid, [7-(1H-indol-2-yl)-1H-imidazo[4,5-b]pyridin-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 562084-01-9 CAPLUS

CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-(1H-indol-2-yl)- (9CI) (CA INDEX NAME)




RN 562084-02-0 CAPLUS

CN 2H-Imidazo[4,5-b]pyridin-2-one, 5-amino-1,3-dihydro-7-(1H-indol-2-yl)- (9CI) (CA INDEX NAME)




RN 562084-03-1 CAPLUS

CN 1H-Imidazo[4,5-b]pyridine-2,5-diamine, 7-(1H-indol-2-yl)- (9CI) (CA INDEX NAME)




RN 562084-04-2 CAPLUS

CN 5H-Imidazo[4,5-b]pyridin-5-one, 1,4-dihydro-2-methyl-7-[5-[[methyl(phenylmethyl)amino]methyl]-1H-indol-2-yl]- (9CI) (CA INDEX NAME)



IT 561307-19-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of indolyldeazapurines for use in pharmaceutical compns. for
 treatment of inflammatory, autoimmune and proliferative diseases)
 RN 561307-19-5 CAPLUS
 CN 1H-Imidazo[4,5-b]pyridin-5-amine, 7-[5-[[[(1,1-
 dimethylethyl)dimethylsilyl]oxy]methyl]-1H-indol-2-yl]-2-methyl- (9CI)
 (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 20:07:32 ON 30 JUL 2007)

FILE 'REGISTRY' ENTERED AT 20:07:40 ON 30 JUL 2007

L1 STRUCTURE UPLOADED
 L2 4 S L1
 L3 4 S L1
 L4 113 S L1 FULL

FILE 'CAPLUS' ENTERED AT 20:08:13 ON 30 JUL 2007

L5 3 S L4 FULL

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
18.16	190.47

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-2.34	-2.34

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 20:11:16 ON 30 JUL 2007